Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order.
Get 50% off discount for CGT related product lines!
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one!
Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers !
Time Limited Offer: Welcome Gift for New Customers !
Items | Size (2mg) | Size(5mg X 2) |
Particle size | 2 μm | 2 μm |
Physical appearance | Powder mixture | Powder mixture |
Amount of Coupled Protein | ≈484 pmol (35 μg) EGFR/mg Beads | ≈484 pmol (35 μg) EGFR/mg Beads |
Binding Capacity | >133 pmol (20 μg) antibody/mg beads | >133 pmol (20 μg) antibody/mg beads |
Formulation | PBS, pH7.4, with 10% Trehalose | PBS, pH7.4, with 10% Trehalose |
Reconstitution | 2 mL sterile deionized water (1 mg beads/mL) | 5 mL sterile deionized water (1 mg beads/mL) |
See Certificate of Analysis (CoA) for detailed instruction.
The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
Immobilized 35 μg EGFR protein to 1 mg Beads, can bind the Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.737 μg/mL.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $800.00
Price(USD) : $2500.00
ACROBiosystems offers a wide selection of Matrigengel basement membrane extracts. Different versions – including phenol red-free, high concentration, iPSC culturing, organoid culturing – are all available for your specific needs to support 3D cell culture!
ComboX is a new brand of ACROBiosystems. ComboX products include our Streptavidin series products, coated plates, isotype controls for antibody and fusion protein drug research, and general-purpose antibodies.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro is ACROBiosystems brand focused on neuroscience research, providing high-quality important proteins including therapeutic and diagnostic research proteins, PFFs and recombinant neuro factors, etc. to advance neuroscience research.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Dacomitinib | PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Europe Ma Eeig | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Penile Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Liver Diseases; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Squamous Cell Carcinoma of Head and Neck | Merck Serono Co Ltd | 2004-02-12 | Endometrial Neoplasms; Oropharyngeal Neoplasms; Peritoneal Neoplasms; Neuralgia; Fallopian Tube Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Laryngeal Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Adenocarcinoma, Mucinous; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Precancerous Conditions; Complex Regional Pain Syndromes; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Colonic Neoplasms; Head and Neck Neoplasms; Neoplastic Cells, Circulating; Liver Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Pain; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Hypopharyngeal Neoplasms; Neoplasms, Squamous Cell; Carcinoma, Adenoid Cystic; Nasopharyngeal Carcinoma; Sarcoma | Details |
Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Skin Ulcer; Burns | Details | ||
Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Nippon Kayaku Co Ltd | 2015-11-24 | Solid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | ||
Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Praxis Pharmaceuticals, Center For Genetic Engineering And Biotechnology | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Diabetic Foot; Burns | Details | |
Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Diabetic Foot; Alopecia; Dry Eye Syndromes | Details |
Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Diabetic Foot; Burns | Details | |
Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Aspyrian Therapeutics | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Breast Neoplasms; Neuroma, Acoustic; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Brain metastases; Esophageal adenocarcinoma; Lung Neoplasms; Carcinoma, Adenosquamous; Solid tumours; Nasopharyngeal Carcinoma; Psoriasis; Adenocarcinoma of Lung; Neurofibromatosis 2; Bronchial Neoplasms; Esophageal Neoplasms; Stomach Neoplasms | Details |
Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Glaxosmithkline Ag | 2007-03-13 | Neoplasms, Gonadal Tissue; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Colorectal Neoplasms; Astrocytoma; Gliosarcoma; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Brain metastases; Lung Neoplasms; Endometrial Neoplasms; Brain Neoplasms; Laryngeal Neoplasms; Gallbladder Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Tongue Neoplasms; Melanoma; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Pancreatic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Ependymoma; Liver Neoplasms; Medulloblastoma; Stomach Neoplasms; Esophageal Neoplasms; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Ovarian Epithelial; Solid tumours; Carcinoma, Verrucous; Glioblastoma; Salivary Gland Neoplasms; Neoplasms; Neurofibromatosis 2; Urinary Bladder Neoplasms; Carcinoma, Adenoid Cystic; Central Nervous System Neoplasms; Oligodendroglioma; Breast Neoplasms; Prost | Details |
Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details | |||||
Afatinib Dimaleate | BIBW-2992; BIBW-2992-MA2 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Tomtovok, 吉泰瑞, Tovok, Giotrif | United States | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim International Gmbh | 2013-07-12 | Uterine Neoplasms; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Lymphoma; Breast Neoplasms; Glioma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Hematologic Neoplasms; Liver Diseases; Urinary Bladder Neoplasms; Chordoma; Multiple Myeloma; Neuroectodermal Tumors; Glioblastoma; Neoplasms; Neoplasms, Squamous Cell; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rhabdomyosarcoma; Head and Neck Neoplasms; Solid tumours | Details |
Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | United States | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Osi Pharmaceuticals Llc | 2004-11-18 | Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Glioma; Bile Duct Neoplasms; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Ureteral Neoplasms; Gliosarcoma; Oropharyngeal Neoplasms; Neuroectodermal Tumors, Primitive; Esophageal adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Astrocytoma; Glioma, Subependymal; Metaplasia; Psoriasis; Osteosarcoma; Sarcoma; Urethral Neoplasms; Neuroblastoma; Prostatic Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Melanoma; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Tongue Neoplasms; Meningioma; Precancerous Conditions; Uterine Cervical Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Cholangitis, Sclerosing; Lip Neoplasms; Gallbladder Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Laryngeal Neoplasms; Adenomatous Polyps; Paranasal Sinus Neoplasms; Adenocarcinoma, Mucinous; Neoplasms, Unknown Primary; Endomet | Details |
Brigatinib | AP-26113 | Approved | Ariad, Takeda Pharmaceutical Co Ltd | Alunbrig | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Ependymoma; Solid tumours; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Granuloma, Plasma Cell; Carcinoma, Non-Small-Cell Lung; Meningioma; Neurilemmoma; Neuroma, Acoustic; Sarcoma, Kaposi | Details |
Gefitinib | ZD-1839 | Approved | Astrazeneca Pharmaceutical Co Ltd | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Fallopian Tube Neoplasms; Gastrinoma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Astrocytoma; Gliosarcoma; Colorectal Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Mucoepidermoid; Lung Neoplasms; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Adenosquamous; Endometrial Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Somatostatinoma; Neoplasm Metastasis; Adenocarcinoma; Glioblastoma; Liver Neoplasms; Solid tumours; Kidney Neoplasms; Ovarian Neoplasms; Carcinoma, Islet Cell; Vipoma; Insulinoma; Carcinoid Tumor; Abdominal Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Head and Neck Neoplasms; Skin Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Adenocarcinoma of Lung; Small Cell Lung Carcinoma; Salivary Gland Neoplasms; | Details |
Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Neratinib Maleate | CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 | Approved | Pfizer Pharmaceuticals Ltd (China) | Nerlynx, 贺俪安 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Panitumumab | ABX-0303; E7.6.3; AMG-954; ABX-EGF; ABX-10221 | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Salivary Gland Neoplasms; Gastrointestinal Neoplasms; Exanthema; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Glioma; Carcinoma, Squamous Cell; Lung Neoplasms; Adenoma, Pleomorphic; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Kidney Neoplasms; Malignant Carcinoid Syndrome; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Rectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
Lazertinib | YH-25448; JNJ-73841937; JNJ-1937; GNS-1480 | Approved | Oscotec Inc, Janssen Biotech Inc, Yuhan Corp | Leclaza | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung | Details |
Nimotuzumab | OSAG-10; KI-0502; KI-0501; DE-766; YMB-1000; OSAG-101; h-R3; TheraCIMh-R3 | Approved | Center Of Molecular Immunology, Cimym Biosciences | Theraloc, BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher | India | Nasopharyngeal Neoplasms; Head and Neck Neoplasms | null | 2006-07-21 | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Anus Neoplasms; Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Pancreatic neuroendocrine tumors (pNET); Nasopharyngeal Diseases; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Glioma; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Esophageal Diseases | Details |
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
Amivantamab | JNJ-372; JNJ-61186372 | Approved | Janssen Global Services Llc, Genmab A/S | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Antroquinonol | Phase 2 Clinical | Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Hepatitis B; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Hyperlipidemias; Dermatitis, Atopic | Details | ||
Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm | Head and Neck Neoplasms; Pancreatic Neoplasms | Details |
D2C7-based immunotoxins (Duke University) | D2C7-IT; scds-D2C7 -PE38KDEL; D2C7-(scdsFv)-PE38 KDEL | Phase 1 Clinical | Istari Oncology Inc, Duke University | Glioma | Details |
WSD-0922 | WSD0922; WSD-0922 | Phase 1 Clinical | Vision Biological Tech (Hefei) Co Ltd | Glioblastoma; Glioma | Details |
CKD-702 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung | Details | |
Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 1 Clinical | Umcg The University Medical Center Groningen | Rectal Neoplasms; Penile Neoplasms | Details | |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
BNA-035 | BNA-035 | Phase 1 Clinical | Binacea Pharma Inc | Solid tumours | Details |
ERAS-801 | ERAS-801 | Phase 1 Clinical | Regents Of The University Of California | Glioblastoma | Details |
REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours; Neoplasms | Details |
HS-10376 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
DAJH-1050766 | DAJH-1050766; DAJH1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
Recombinant anti-InE monoclonal antibody | CmAb-(IL10)2 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 1 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms | Details |
Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
SGT-210 | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
Anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) | EGFR-806 | Phase 1 Clinical | Seattle Children'S Hospital | Central Nervous System Neoplasms | Details |
TQB-3456 | TQB-3456 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi Zhikang Hongyi Biological Technology Co Ltd | Solid tumours | Details |
YK-029A | YK-029A | Phase 1 Clinical | Hainan Yuekang Biomedicine Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
AP-L1898 | JS111; AP-L1898; WJ-002 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Epitinib Succinate | HMPL-813 | Phase 1 Clinical | Hutchison Medipharma Ltd | Solid tumours; Neoplasms; Glioblastoma; Carcinoma, Non-Small-Cell Lung | Details |
Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Bronchial Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
BL-B01D1 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Neoplasms, Fibroepithelial; Solid tumours; Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms | Details | |
Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Head and Neck Neoplasms; Brain Neoplasms | Details | |
QL1203 | QL-1203 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Liver Neoplasms; Biliary Tract Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular | Details |
H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BDTX-1535 | BDTX-1535 | Phase 1 Clinical | Black Diamond Therapeutics Inc | Glioblastoma; Carcinoma, Non-Small-Cell Lung | Details |
BEBT-109 | BEBT-109 | Phase 2 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | Korean Green Cross Corp | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
WJ-13404 | WJ-13404; JS-113; WJ-004 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Cetuximab biosimilar (AMPO Biotechnology) | Phase 3 Clinical | Ampo Biotechnology Inc | Colorectal Neoplasms | Details | |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Cetuximab biosimilar (Shanghai Zhangjiang Biotechnology) | STI-001; CMAB-009 | Phase 3 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Neoplasms; Colorectal Neoplasms | Details |
TQB3804 | TQB-3804 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
[111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms | Details | |
EGFR IL12 CART | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
ZN-e4 | ZN-e4; KP-673 | Phase 2 Clinical | Zentalis Pharmaceuticals LLC, Zeno Pharma | Carcinoma, Non-Small-Cell Lung | Details |
QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
FCN-411 | FCN-411 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Lung Diseases; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Losatuxizumab vedotin | ABBV221; ABBV-221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
Hemay-020 | Hemay-020 | Phase 1 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
BPI-15086 | BPI-15000; BPI-15086 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
ORIC-114 | ORIC-114 | Phase 1 Clinical | Voronoi | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
BLU-701 | BLU 701; BLU-701 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Antibody-drug nanocell conjugates (EnGeneIC) | EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox | Phase 1 Clinical | Engeneic Ltd | Glioblastoma | Details |
FWD1509 MsOH | FWD1509 MsOH | Phase 2 Clinical | Shenzhen Forward Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
ABY-029 | ABY-029 | Phase 1 Clinical | Dartmouth College, Affibody Ab, Li-Cor Bioscience | Head and Neck Neoplasms; Sarcoma; Glioma | Details |
HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
Autologous EGFR-CAR T cells (Bio-gene) | Phase 1 Clinical | Sun Yat-Sen University, Guangzhou Bio-Gene Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
PLB-1004 | PLB-1004 | Phase 1 Clinical | Beijing Anshi Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms | Details |
Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Advenchen Laboratories Llc | Carcinoma, Non-Small-Cell Lung | Details |
EG-007 | EG-007 | Phase 3 Clinical | Evergreen Therapeutics Inc | Endometrial Neoplasms | Details |
GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details | |
ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
BLU-451 | BLU-451 | Phase 2 Clinical | Blueprint Medicines Corp | Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms | Details | |
ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
JMT101 | JMT-101 | Phase 3 Clinical | Shanghai Jinmante Biological Technology Co Ltd | Solid tumours; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Solid tumours; Head and Neck Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma; Pancreatic Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Colorectal Neoplasms | Details |
LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 3 Clinical | Symphogen A/S | Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Glioma | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma; Squamous Cell Carcinoma of Head and Neck | Details |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 1 Clinical | National Cheng Kung University, Blue Blood Biotech Corp | Diabetic Foot | Details |
ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
BBT-176 | BBT-176 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
TAS-6417 | CLN-081; TAS-6417 | Phase 2 Clinical | Taiho Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
SMET-12 | SMET-12 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Lifirafenib | BeiGene-283; BGB-283 | Phase 2 Clinical | Beigene Ltd | Solid tumours | Details |
Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Pancreatic Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Cetuximab biosimilar (Kelun Group) | KL-A140; KLA140; A-140; KL-140; KLA-140 | Phase 3 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Rectal Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Adenocarcinoma | Details |
Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Colorectal Neoplasms | Details | ||
M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IAE-0972 | IAE-0972 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours | Details |
DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd | Colorectal Neoplasms | Details |
Petosemtamab | MCLA-158 | Phase 1 Clinical | Merus Nv | Neoplasms; Colorectal Neoplasms | Details |
TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms | Details | |
[89Zr]Panitumumab (University of Alabama at Birmingham) | Phase 1 Clinical | University Of Alabama At Birmingham | Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Pancreatic Neoplasms | Details | |
TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Neoplasms | Details |
CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Solid tumours | Details |
Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
Tarloxotinib Bromide | PR-610; TH-4000; SN-33999 | Phase 2 Clinical | Threshold | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details |
Sutetinib Maleate | Phase 2 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
DBPR-112 | DBPR-112; ABT-101 | Phase 2 Clinical | National Health Research Institutes | Head and Neck Neoplasms; Solid tumours; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
BAY-2927088 | BAY-2927088; BAY2927088 | Phase 1 Clinical | Bayer Healthcare Company Ltd, Bayer AG | Carcinoma, Non-Small-Cell Lung | Details |
MRG003 | MRG-003 | Phase 3 Clinical | Shanghai Miracogen Inc | Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MCLA-129 | MCLA-129 | Phase 2 Clinical | Merus Nv | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
DK-2-10 | DK210 | Phase 1 Clinical | Deka Biosciences Inc | Solid tumours; Kidney Neoplasms; Head and Neck Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Skin Neoplasms; Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BB-1705 | BB-1705 | Phase 2 Clinical | Solid tumours; Neoplasms; Neoplasm Metastasis | Details | |
AZD9592 | AZD9592; AZD-9592 | Phase 1 Clinical | Astrazeneca Plc | Head and Neck Neoplasms; Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
TQ-B3395 | TQ-B3395; CT-1495; TQ-B-3395 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Neoplasms; Breast Neoplasms | Details |
ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
HLX-35 | HLX-35 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Depatuxizumab mafodotin | ABT-414/806; ABT-414 | Phase 3 Clinical | Abbvie Inc | Glioblastoma; Gliosarcoma; Glioma; Carcinoma, Squamous Cell | Details |
Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms | Details |
JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Solid tumours; Neoplasms; Macular Degeneration | Details |
WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Pimurutamab | HLX-07 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Adenosquamous; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Varlitinib Ditosylate | QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 | Phase 2 Clinical | Array Biopharma | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Bile Duct Neoplasms | Details |
Mefatinib | Phase 3 Clinical | Suzhou Maitai Bio-Technology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.